| TIDM | Instrument | Type | Currency | Venue |
|---|---|---|---|---|
| ALZN | ALZN | Shares | USD | XNCM |
| TIDM | Instrument | Type | Currency | Venue |
|---|---|---|---|---|
| ALZN | ALZN | Shares | USD | XNCM |
Alzamend Neuro, Inc. is a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological and psychiatric disorders, specifically Alzheimer's disease, Major Depressive Disorder, Bipolar Disorder, and Post-Traumatic Stress Disorder. The company operates a pipeline that includes two primary drug candidates: AL001, which utilizes patented ionic cocrystal technology to deliver lithium in combination with proline and salicylate, and ALZN002, a cell-based therapeutic vaccine aimed at enhancing the immune response against Alzheimer's disease. Alzamend Neuro is headquartered in Atlanta, Georgia.
No recent RNS announcements for ALZN across ALZN.
No recent RNS announcements for ALZN across ALZN.